{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:28Z","timestamp":1790014828626,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejphar.2026.179034","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:28:51Z","timestamp":1780122531000},"page":"179034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Sustained ranibizumab port delivery for disease modification and treatment durability in diabetic retinopathy and diabetic macular edema: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"1031","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179034_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/diabetology3010011","article-title":"Diabetic retinopathy: an overview on mechanisms, pathophysiology and pharmacotherapy","volume":"3","author":"Ansari","year":"2022","journal-title":"Diabetology"},{"key":"10.1016\/j.ejphar.2026.179034_bib2","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s40123-023-00750-9","article-title":"Real-world persistence and treatment interval in patients with diabetic macular edema treated with anti-vascular endothelial growth factors in the USA","volume":"12","author":"Bakri","year":"2023","journal-title":"Ophthalmology and Therapy"},{"key":"10.1016\/j.ejphar.2026.179034_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/OPTH.S128509","article-title":"Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO study report 1)","volume":"11","author":"Blinder","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejphar.2026.179034_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/9781119099369.ch27","article-title":"Comprehensive meta-analysis software","author":"Borenstein","year":"2022","journal-title":"Systematic Reviews in Health Research: Meta-Analysis in Context"},{"key":"10.1016\/j.ejphar.2026.179034_bib5","article-title":"Diabetic macular edema management: a review of anti-vascular endothelial growth factor (VEGF) therapies","volume":"16","author":"Cheema","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2026.179034_bib35","doi-asserted-by":"crossref","first-page":"112379","DOI":"10.1016\/j.diabres.2025.112379","article-title":"Which treatment modality offers the best outcomes for diabetic retinopathy? A systematic review and network meta-analysis","volume":"227","author":"Chen","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2026.179034_bib6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.survophthal.2025.05.008","article-title":"Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: a systematic review and network meta-analysis of randomized controlled trials","volume":"70","author":"Chen","year":"2025","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejphar.2026.179034_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/17439760.2016.1262613","article-title":"Thematic analysis","volume":"12","author":"Clarke","year":"2017","journal-title":"J. Posit. Psychol."},{"key":"10.1016\/j.ejphar.2026.179034_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2013","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.ejphar.2026.179034_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001104","article-title":"Ranibizumab port delivery system: a clinical perspective","volume":"7","author":"Eichenbaum","year":"2022","journal-title":"BMJ Open Ophthalmology"},{"key":"10.1016\/j.ejphar.2026.179034_bib1001","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","article-title":"End-of-study results for the ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"5","author":"Khanani","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.ejphar.2026.179034_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","article-title":"Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the PAGODA randomized clinical trial","volume":"143","author":"Khanani","year":"2025","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.ejphar.2026.179034_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.18553\/jmcp.2020.19245","article-title":"Real-world injection frequency and cost of ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration and diabetic macular edema","volume":"26","author":"Kiss","year":"2020","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1016\/j.ejphar.2026.179034_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13167-023-00314-8","article-title":"Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications: risks and mitigation","volume":"14","author":"Kropp","year":"2023","journal-title":"EPMA J."},{"key":"10.1016\/j.ejphar.2026.179034_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s42399-025-01971-8","article-title":"Revolutionizing diabetic macular edema treatment: FDA approval of Susvimo","volume":"7","author":"Kumar","year":"2025","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.ejphar.2026.179034_bib15","article-title":"Port delivery system with ranibizumab (PDS) met primary endpoint and key secondary outcomes with >75% of patients preferring PDS treatment in phase 3 PAVILION trial for diabetic retinopathy (DR)","volume":"65","author":"Latkany","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejphar.2026.179034_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye and Vision"},{"key":"10.1016\/j.ejphar.2026.179034_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40123-023-00843-5","article-title":"Clinical trials and future outlooks of the port delivery system with ranibizumab: a narrative review","volume":"13","author":"Lowater","year":"2024","journal-title":"Ophthalmology and Therapy"},{"key":"10.1016\/j.ejphar.2026.179034_bib18","article-title":"Port delivery system with ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 PAGODA trial","volume":"65","author":"Malhotra","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejphar.2026.179034_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.ejphar.2026.179034_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.ejphar.2026.179034_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4239\/wjd.v6.i3.489","article-title":"Diabetic retinopathy: ocular complications of diabetes mellitus","volume":"6","author":"Nentwich","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.ejphar.2026.179034_bib22","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2147\/OPTH.S304229","article-title":"Visual function for driving in diabetic macular edema and retinal vein occlusion post-stabilization with anti-vascular endothelial growth factor","volume":"15","author":"Nixon","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejphar.2026.179034_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.ejphar.2026.179034_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaophthalmol.2025.0001","article-title":"Port delivery system with ranibizumab vs monitoring in nonproliferative diabetic retinopathy without macular edema: the PAVILION randomized clinical trial","volume":"143","author":"Pieramici","year":"2025","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ejphar.2026.179034_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/tvst.14.4.8","article-title":"Structural updates to the implant and refill needle of the Port Delivery Platform","volume":"14","author":"Pieramici","year":"2025","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ejphar.2026.179034_bib25","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/pharmaceutics15051484","article-title":"Delivery systems in ocular retinopathies: the promising future of intravitreal hydrogels as sustained-release scaffolds","volume":"15","author":"Rafael","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2026.179034_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40942-024-00603-y","article-title":"Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights","volume":"10","author":"Sakini","year":"2024","journal-title":"International Journal of Retina and Vitreous"},{"key":"10.1016\/j.ejphar.2026.179034_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40942-023-00446-z","article-title":"Port delivery system with ranibizumab (Susvimo) recall: what does it mean to the retina specialists","volume":"9","author":"Sharma","year":"2023","journal-title":"International Journal of Retina and Vitreous"},{"key":"10.1016\/j.ejphar.2026.179034_bib28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3389\/fendo.2019.00843","article-title":"Diabetic retinopathy: an underdiagnosed and undertreated inflammatory, neuro-vascular complication of diabetes","volume":"10","author":"Sinclair","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2026.179034_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2147\/OPTH.S100168","article-title":"Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion","volume":"10","author":"Sivaprasad","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejphar.2026.179034_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/17512433.2014.884458","article-title":"Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF","volume":"7","author":"Stewart","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179034_bib31","article-title":"Clinical update: FDA approval of susvimo\u2122 for neovascular age-related macular degeneration","author":"Sund","year":"2022","journal-title":"The Retina Care Center"},{"key":"10.1016\/j.ejphar.2026.179034_bib32","article-title":"Port delivery system with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from PAGODA and PAVILION phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR)","volume":"65","author":"Wirthlin","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejphar.2026.179034_bib33","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.ejphar.2026.179034_bib34","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2026.179034_bib36","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.179034_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40123-024-01060-4","article-title":"Improving clinical management of diabetic macular edema: insights from a global survey of patients, healthcare providers, and clinic staff","volume":"14","author":"Ziemssen","year":"2025","journal-title":"Ophthalmology and Therapy"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926005169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926005169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:15:15Z","timestamp":1786652115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926005169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"alternative-id":["S0014299926005169"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179034","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained ranibizumab port delivery for disease modification and treatment durability in diabetic retinopathy and diabetic macular edema: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"179034"}}